A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions; Therapeutic Use
- Acronyms REAL 3
- Sponsors Novo Nordisk
- 11 Oct 2024 Status changed from recruiting to completed.
- 18 Sep 2024 This trial has been completed in Slovenia ,according to the European Clinical Trials Database record.
- 28 Oct 2023 This trial has been completed in Germany (Date of the global end of the trial: 02-Oct-2023), according to the European Clinical Trials Database record.